VECLAM ® is a Clarithromycin-based drug
THERAPEUTIC GROUP: Antibacterials - antibacterials for systemic use, macrolides
Indications VECLAM © Clarithromycin
VECLAM © is an antibiotic generally used in the treatment of infectious diseases caused by microorganisms sensitive to macrolides and in particular to Clarithromycin.
Clinically, this antibacterial chemotherapy is mainly used in the treatment of infectious diseases of the respiratory tract, skin and soft tissues and in the treatment of Mycobacterium and Helicobacter Pylori infections.
Mechanism of action VECLAM © Clarithromycin
Clarithromycin, active principle of VECLAM ©, is a semi-synthetic antibiotic belonging to the category of macrolides with 14 carbon atoms, obtained starting from the progenitor of this family, erythromycin from which it essentially differs for some pharmacokinetic characteristics.
From a therapeutic point of view, in fact, both the spectrum of sensitive microorganisms, Gram positive and Gram negative cocci and bacilli, and the mechanism of action, characterized by the inhibition of protein synthesis mediated by the link with the 50S ribosomal subunit, is completely superimposable.
The better stability in an acid environment and a significant reduction of gastro-enteric side effects, on the other hand, represent the peculiar characteristics of Clarithromycin, which give it a better method of use.
However, the main resistance mechanisms put in place by microorganisms to reduce the therapeutic efficacy of Clarithromycin remain active, including:
- Reduction of membrane permeability with the expression of efflux pumps which prevent the active principle from reaching therapeutic concentrations inside the cell;
- Variation of the binding site, thus preventing specific interaction with the target;
- Expression of enzymes capable of inactivating the antibiotic.
Studies carried out and clinical efficacy
1. CLARITHROMYCIN IN THE TREATMENT OF ACUTE ASTHMA
Pediatr Allergy Immunol. 2012 Jun; 23: 385-90
Effect of clarithromycin on acute asthma exacerbations in children: an open randomized study.
Koutsoubari I, Papaevangelou V, Konstantinou GN, Makrinioti H, Xepapadaki P, Kafetzis D, Papadopoulos NG.
Work that demonstrates how treatment with Clarithromycin can lead to a reduction in respiratory symptoms present in acute asthma, controlling the episodes of exacerbation and thus improving the quality of life of affected patients.
2 . PASS RESISTANCE OF H.PYLORI TO CLARITHROMYCIN
Gastroenterol Res Pract. 2012; 2012: 418010. Epub 2012 May 27.
Variability in Prevalence of Helicobacter pylori Strains Resistant toClarithromycin and Levofloxacin in Southern Poland.
Karczewska E, Klesiewicz K, Skiba I, Wojtas-Bonior I, Site E, Czajecki K, Zwolińska-Wcisło M, Budak A.
Study that demonstrates how Clarithromycin still represents one of the most used antibiotics in the "eradication of" H. Pylori, given the low number of strains resistant to this therapy.
3. CLARITHROMYCIN IN DERMATOLOGICAL PATHOLOGIES
Wien Klin Wochenschr. 2012 Jul; 124 (13-14): 427-33. Epub 2012 Jul 4.
Solitary erythema migrans in children: comparison of treatment withclarithromycin and amoxicillin.
Nizič T, Velikanje E, Ružić-Sabljić E, Arnež M.
Study demonstrating the efficacy of Clarithromycin in the treatment of dermatological pathologies characterized by migrating edema, without the development of particular adverse reactions.
Method of use and dosage
VECLAM ©
Coated tablets of 250 - 500 mg of Clarithromycin;
Clarithromycin 125-250 mg granules for oral suspension per 5 ml of solution;
Clarithromycin 500 mg modified-release tablets.
Generally the daily intake of 500-2000 mg of Clarithromycin at two different times, with the exception of the modified release tablets, which can be taken in single administration, is effective in most of the infectious pathologies sustained by microorganisms sensitive to macrolides.
A dosage adjustment, as well as in patients with liver and kidney disease, should be envisaged in the combination therapy for the eradication of Helicobacter Pylori.
Warnings VECLAM © Clarithromycin
The use of VECLAM © should be preceded by a medical examination useful to evaluate the entity of the pathological picture and characterize:
- The responsible microorganism and its sensitivity to Clarithromycin;
- The possible presence of contraindications to the use of this antibiotic, such as liver, kidney and cardiovascular diseases;
- Any pharmacological therapies in place, responsible for clinically relevant drug interactions.
It is also useful to remember that therapy should be limited to the time strictly necessary in order to avoid the overlap of bacterial infections potentially responsible for pathologies such as pseudomembranous colitis caused by Clostridium Difficile.
VECLAM © contains glucose and lactose, therefore not indicated in patients with diabetes or glucose / galactose malabsorption syndrome,
lactose intolerance and lactase enzyme deficiency.
PREGNANCY AND BREASTFEEDING
The use of VECLAM © is contraindicated during pregnancy and in the subsequent breastfeeding period, given the absence of clinical trials able to clarify the safety profile of Clarithromycin on the fetus and given the ability of this active ingredient to be excreted. in breast milk in significant concentrations.
Interactions
In order to limit the possible onset of serious side effects, it is necessary to consult your doctor carefully before undertaking the simultaneous intake of several active ingredients.
More precisely, particular caution should be reserved for the administration of all those drugs metabolized by the enzyme system of cytochromes, punctually inhibited by Clarithromycin, such as alprazolam, oral anticoagulants, astemizole, carbamazepine, cilostazol, cisapride, cyclosporine, disopyramide, rye alkaloids, lovedisol , midazolam, omeprazole, pimozide, quinidine, rifabutin, sildenafil, simvastatin, tacrolimus, terfenadine, triazolam and vinblastine.
Contraindications VECLAM © Clarithromycin
The use of STREPTOSIL ® is contraindicated in case of hypersensitivity to the active principle and to the relative excipients.
It is also remembered to avoid contact of the drug with the mucous membranes and the conjunctiva.
Undesirable Effects - Side Effects
VECLAM © is contraindicated in patients with hypersensitivity to the active substance or to one of its excipients, severe hepatic insufficiency or concomitant therapy with ergotamine or alkaloids with marked vasoconstrictive activity and statins.
Note
VECLAM © is a drug subject to mandatory medical prescription.
The information on VECLAM © Clarithromycin published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
